BIS
ProShares UltraShort Nasdaq Biotechnology
Price Chart
Latest Quote
$16.34
-0.33 (-1.98%)
Current Price
| Previous Close | $16.67 |
| Open | $16.59 |
| Day High | $16.60 |
| Day Low | $15.99 |
| Volume | 6,773 |
Fund Information
| Quarterly Dividend / Yield | N/A / 5.21% |
| Net Assets | $2.42M |
| Expense Ratio | 0.95% |
| Category | Trading--Inverse Equity |
| Fund Family | ProShares |
| Net Asset Value | $16.34 |
| Premium/Discount | 0.02% |
| Quarterly Dividend Yield | 5.21% |
| Exchange | NGM |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $17.11 |
| SMA50 | $17.07 |
| SMA200 | $19.47 |
| RSI | 48.23 |
| ATR | 0.6343 |
| Rel Volume | 1.02 |
Performance History
| Week | -8.36% |
| Month | -10.51% |
| Quarter | -13.48% |
| 6 Months | -12.87% |
| YTD | -13.30% |
| Year | -51.25% |
| 3 Years | -54.49% |
| 5 Years | -51.38% |
| 10 Years | -94.47% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $16.34 | 6,800 |
| 2026-06-16 | $16.70 | 3,200 |
| 2026-06-15 | $16.59 | 700 |
| 2026-06-12 | $16.80 | 4,200 |
| 2026-06-11 | $16.86 | 3,200 |
| 2026-06-10 | $17.83 | 6,100 |
| 2026-06-09 | $17.19 | 11,100 |
| 2026-06-08 | $17.73 | 10,700 |
| 2026-06-05 | $17.37 | 5,700 |
| 2026-06-04 | $16.78 | 10,300 |
| 2026-06-03 | $17.63 | 9,200 |
| 2026-06-02 | $18.30 | 17,300 |
| 2026-06-01 | $17.26 | 7,200 |
| 2026-05-29 | $16.63 | 1,500 |
| 2026-05-28 | $16.59 | 2,600 |
| 2026-05-27 | $16.94 | 2,650 |
| 2026-05-26 | $17.06 | 2,400 |
| 2026-05-22 | $17.18 | 1,700 |
| 2026-05-21 | $17.08 | 10,350 |
| 2026-05-20 | $17.36 | 16,600 |
| 2026-05-19 | $18.20 | 5,050 |
| 2026-05-18 | $18.26 | 8,500 |
About ProShares UltraShort Nasdaq Biotechnology
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain inverse leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.